))
The Role of Immunotherapy in the Treatment of Recurrent or Metastatic HNSCC: The Evidence
Manage episode 416273244 series 3381434
Innehåll tillhandahållet av ReachMD. Allt poddinnehåll inklusive avsnitt, grafik och podcastbeskrivningar laddas upp och tillhandahålls direkt av ReachMD eller deras podcastplattformspartner. Om du tror att någon använder ditt upphovsrättsskyddade verk utan din tillåtelse kan du följa processen som beskrivs här https://sv.player.fm/legal.
CME credits: 0.50
Valid until: 03-05-2025
Claim your CME credit at https://reachmd.com/programs/cme/the-role-of-immunotherapy-in-the-treatment-of-recurrent-or-metastatic-hnscc-the-evidence/24355/
In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.
…
continue reading
Valid until: 03-05-2025
Claim your CME credit at https://reachmd.com/programs/cme/the-role-of-immunotherapy-in-the-treatment-of-recurrent-or-metastatic-hnscc-the-evidence/24355/
In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.
680 episoder
Dela
